Predictors of malignancy in patients with pheochromocytomas/paragangliomas: Asian Indian experience
暂无分享,去创建一个
N. Shah | A. Bhansali | K. Khadilkar | G. Malhotra | R. Rajput | V. Shivane | A. Dalvi | V. Sarathi | R. Pandit | Rajeev Kasaliwal | A. Lila | T. Bandgar | G. Bakshi | M. Goroshi
[1] O. Dekkers,et al. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. , 2016, European journal of endocrinology.
[2] Jungsuk An,et al. Phenylethanolamine N-methyltransferase downregulation is associated with malignant pheochromocytoma/paraganglioma , 2016, Oncotarget.
[3] S. Khare,et al. Germline mutations and genotype-phenotype correlation in Asian Indian patients with pheochromocytoma and paraganglioma. , 2016, European journal of endocrinology.
[4] K. Pacak,et al. 15 YEARS OF PARAGANGLIOMA: Imaging and imaging-based treatment of pheochromocytoma and paraganglioma. , 2015, Endocrine-related cancer.
[5] S. Fanti,et al. Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies - a multicenter experience. , 2015, Hellenic journal of nuclear medicine.
[6] Elise M. Blanchet,et al. Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma , 2015, Clinical Cancer Research.
[7] E. Baudin,et al. Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. , 2014, European journal of endocrinology.
[8] T. Fojo,et al. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study , 2014, BMC Cancer.
[9] W. Young,et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.
[10] P. Castaldi,et al. Comparison of metaiodobenzylguanidine scintigraphy with positron emission tomography in the diagnostic work-up of pheochromocytoma and paraganglioma: a systematic review. , 2013, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[11] S. Bornstein,et al. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. , 2012, European journal of cancer.
[12] B. Paghera,et al. Role of 18F-FDG PET/CT, 123I-MIBG SPECT, and CT in Restaging Patients Affected by Malignant Pheochromocytoma , 2011, Nuclear medicine and molecular imaging.
[13] F. Feng,et al. Predictive factors for malignant pheochromocytoma: analysis of 136 patients. , 2011, The Journal of urology.
[14] Lei Feng,et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. , 2011, The Journal of clinical endocrinology and metabolism.
[15] Choung-Soo Kim,et al. Predictive Characteristics of Malignant Pheochromocytoma , 2009, Korean journal of urology.
[16] M. Fraenkel,et al. Malignant pheochromocytoma: predictive factors of malignancy and clinical course in 16 patients at a single tertiary medical center , 2011, Endocrine.
[17] G. Arnaldi,et al. Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. , 2009, The Journal of clinical endocrinology and metabolism.
[18] A. González-Neira,et al. Genetics of pheochromocytoma and paraganglioma in Spanish patients. , 2009, The Journal of clinical endocrinology and metabolism.
[19] J. Carrasquillo,et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. , 2009, The Journal of clinical endocrinology and metabolism.
[20] J. Carrasquillo,et al. I-MIBG Scintigraphy in the Localization of Pheochromocytoma and Paraganglioma , 2017 .
[21] A. Tischler. Pheochromocytoma: Time to Stamp Out “Malignancy”? , 2008, Endocrine pathology.
[22] Laura H. Tang,et al. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. , 2008, Surgery.
[23] E. Baudin,et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. , 2007, The Journal of clinical endocrinology and metabolism.
[24] A. Grossman,et al. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. , 2007, Endocrine-related cancer.
[25] S. Richard,et al. Genetic testing in pheochromocytoma or functional paraganglioma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] N. Kimura,et al. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: A clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors , 2005, Endocrine pathology.
[27] Q. Duh,et al. Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas. , 2004, Surgery.
[28] David I. Smith,et al. Malignant pheochromocytoma: current status and initiatives for future progress. , 2004, Endocrine-related cancer.
[29] Jie Gao,et al. [Distinction between benign and malignant pheochromocytomas]. , 2004, Zhonghua bing li xue za zhi = Chinese journal of pathology.
[30] R. DeLellis. Pathology and genetics of tumours of endocrine organs , 2004 .
[31] L. Thompson. Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to Separate Benign From Malignant Neoplasms: A Clinicopathologic and Immunophenotypic Study of 100 Cases , 2002, The American journal of surgical pathology.
[32] D. Hauri,et al. Pheochromocytomas: can malignant potential be predicted? , 1999, Urology.